212 related articles for article (PubMed ID: 9864172)
1. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal.
Delforge M; Boogaerts MA; McGlave PB; Verfaillie CM
Blood; 1999 Jan; 93(1):284-92. PubMed ID: 9864172
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
[TBL] [Abstract][Full Text] [Related]
3. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells.
Verfaillie CM; Bhatia R; Steinbuch M; DeFor T; Hirsch B; Miller JS; Weisdorf D; McGlave PB
Blood; 1998 Sep; 92(5):1820-31. PubMed ID: 9716614
[TBL] [Abstract][Full Text] [Related]
5. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
[TBL] [Abstract][Full Text] [Related]
6. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.
Leemhuis T; Leibowitz D; Cox G; Silver R; Srour EF; Tricot G; Hoffman R
Blood; 1993 Feb; 81(3):801-7. PubMed ID: 7679000
[TBL] [Abstract][Full Text] [Related]
7. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression.
Verfaillie CM; Miller WJ; Boylan K; McGlave PB
Blood; 1992 Feb; 79(4):1003-10. PubMed ID: 1371077
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
[TBL] [Abstract][Full Text] [Related]
9. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia.
Lewis ID; Haylock DN; Moore S; To LB; Hughes TP
Leukemia; 1997 Apr; 11(4):581-7. PubMed ID: 9096699
[TBL] [Abstract][Full Text] [Related]
11. Benign marrow progenitors are enriched in the CD34+/HLA-DRlo population but not in the CD34+/CD38lo population in chronic myeloid leukemia: an analysis using interphase fluorescence in situ hybridization.
Kirk JA; Reems JA; Roecklein BA; Van Devanter DR; Bryant EM; Radich J; Edmands S; Lee A; Torok-Storb B
Blood; 1995 Jul; 86(2):737-43. PubMed ID: 7541674
[TBL] [Abstract][Full Text] [Related]
12. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
13. The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors.
Traycoff CM; Srour EF; Dutt P; Fan Y; Cornetta K
Leukemia; 1997 Jan; 11(1):159-67. PubMed ID: 9001433
[TBL] [Abstract][Full Text] [Related]
14. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
15. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
16. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
Carella AM; Frassoni F; Podestá M; Pungolino E; Pollicardo N; Ferrero R; Soracco M
J Hematother; 1994; 3(3):199-202. PubMed ID: 7530135
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells.
De Fabritiis P; Dowding C; Bungey J; Chase A; Angus G; Szydlo R; Goldman JM
Leuk Lymphoma; 1993 Sep; 11(1-2):51-61. PubMed ID: 7693107
[TBL] [Abstract][Full Text] [Related]
18. Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML.
Heinzinger M; Waller CF; Rosenstiel A; Scheid S; Burger KJ; Lange W
Leukemia; 1998 Mar; 12(3):333-9. PubMed ID: 9529127
[TBL] [Abstract][Full Text] [Related]
19. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Song YP; Fang BJ; Wei XD; Zheng S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
[TBL] [Abstract][Full Text] [Related]
20. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
